fda warning letter bpc-157 2023 FDA's Overreach on Compounded Peptides Trends In FDA FY2023 Inspection-Based
Description
Measuring nanoparticles containing aFGF were blended in polymer solutions to create polymer-shelled particles via electrospraying, and the results showed that this shell structure also promoted sustained protein release [247]
The peptides go through rigorous testing at third-party, unaffiliated labs, where they are tested for purity, potency, and the presence of contaminants
There is no legal pathway under current FDA policy to obtain pharmaceutical-grade BPC-157 or PDA for human use through compounding in the United States
The presence of proinflammatory cytokines promotes the degenerative process, thereby exacerbating degenerative symptoms in IVDs
